A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 May 2016 Results (pooled analysis of this and other nine studies, n = 3993) assessing safety of secukinumab published in the Journal of the American Academy of Dermatology.
    • 05 Mar 2013 Results for the effect of secukinumab on high-sensitivity C-reactive protein presented at the 71st Annual Meeting of the American Academy of Dermatology.
    • 05 Mar 2013 Results with focus on lipid profile and tolerability presented at the 71st Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top